Bibliography
- ARENDT T, HOLZER M, FRUTH R, BRUCKNER MK, GART-NER A: Paired helical filament-like phosphorylation of tau, deposition of tl/A4-amyloid and memory impair-ment in rat induced by chronic inhibition of phos-phatase 1 and 2A. Neuroscience (1995) 69:691–698.
- SELKOE DJ: Cell biology of the amyloid a-protein pre-cursor and the mechanism of Alzheimer's disease. Ann. Rev. Cell Biol. (1994) 10:373–403.
- SAVAGE MJ, HOWLAND DS, ALT SM et al.: APP transgene-sis: approaches towards the development of animal models for Alzheimer's disease neuropathology. In: Neurobiology of Alzheimer's Disease. Dawbarn D, Allen SJ (Eds.), Oios Scientific Publishers, Oxford (1995):149–192.
- GAMES D, ADAMS D, ALESSANDRINI R et al.: Alzheimer-type neuropathology in transgenic mice overexpress-ing V717F tl-amyloid precursor protein. Nature (1995) 373:523–527.
- •First convincing report of an APP transgenic mouse with AD-type amyloid plaques in an appropriate neuroanatomi-cal distribution.
- ARRIAGADA PV, GROWDON JH, HEDLEY-WHTYE ET, HYMAN BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 42:631–639.
- MASLIAH E, SISK A, MALLORY M, MUCKE L, SCHENK D, GAMES D: Comparison of neurodegenerative pathol-ogy in transgenic mice overexpressing V717F 0-am-yloid precursor protein and Alzheimer's disease. J. Neurosci. (1996) 16:5795–5811.
- JOHNSON-WOOD K, LEE M, MOTTER R et al.: Amyloid precursor protein processing and A342 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. ScL USA (1997) 94:1550–1555.
- IRIZARRY MC, SORIANO F, MCNAMARA M et al.: AS depo-sition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. NeuroscL (1997) 17:7053–7059.
- MUCKE L, MASLIAH E, JOHNSON WB et al: Synapto- trophic effects of human amyloid 6 protein precursors in the cortex of transgenic mice. Brain Res. (1994) 666:151–167.
- HSIAO K, CHAPMAN P, NILSEN S et al.: Correlative mem- ory deficits, A6 elevation, and amyloid plaques in transgenic mice. Science (1996) 274:99–102.
- •K670N/M671L transgenic mice with deficits in learning and memory tests which correlated with increased A,6 concen-trations and AD-type neuropathalogical damage.
- IRIZARRY MC, MCNAMARA M, FEDORCHAK K, HSIAO K, HYMAN BT: APP sw transgenic mice develop age-related A6 deposits and neuropil abnormalities, but no neu-ronal loss in CAL J. Neuropathol Exp. Neurol (1997) 56:965–973.
- HOLCOMB L, GORDON MN, MCGOWAN E et al: Acceler-ated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med. (1998) 4:97–100.
- HSIAO KK: Understanding the biology and molecular pathogenesis of Alzheimer's disease in transgenic mice expressing amyloid precursor proteins. In: Mo-lecular Mechanisms ofDementia. Wasco W, Tanzi RE (Eds.), Humana Press, Totawa, NJ (1997):39–43.
- CITRON M, OLTERSDORF T, HAASS C et al.: Mutation of the 6-amyloid precursor protein in familial Alz-heimer's disease increases a-protein production. Na-ture (1992) 360:672–674.
- CAI X, GOLDE TE, YOUNKIN SG: Release of excess amy-loid 6 protein from a mutant amyloid 6 protein precur-sor. Science (1993) 259:514–516.
- SUZUKI N, CHEUNG T, CAI XD et al.: An increased per-centage of long amyloid a-protein secreted by familial amyloid a-protein precursor (APP717) mutants. Sci-ence (1994) 264:1336–1340.
- SCHEUNER D, ECKMAN C, JENSEN M et al: Secreted amy-loid a-protein similar to that in the amyloid plaques of Alzheimer's disease is increased in vivo by the preseni-lin 1 and 2 and APP mutations linked to familial Alz-heimer's disease. Nature Med. (1996) 2:864–870.
- ANDRA K, ABRAMOWSKI D, DUKE M eta].: Expression of APP in transgenic mice: a comparison of neurone-specific promoters. Neurobiol. Aging (1996) 17:183–190.
- BRAAK H, BRAAK E, GRUNDKE-IQBAL I, IQBAL K: Occur-rence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside the neurofibrillary tangles and neuritic plaques. NeuroscL Lett. (1986) 65:351–355.
- LARNER AJ, ROSSOR MN: Alzheimer's disease: towards therapeutic manipulation of the amyloid precursor protein and amyloid 6-peptides. Exp. Opin. Ther. Patents (1997) 7:1115–1127.
- HAASS C, CAPELL A, CITRON M, TEPLOW DB, SELKOE DJ: The vacuolar HtATPase inhibitor bafilomycin Al dif-ferentially affects proteolytic processing of mutant and wild-type 6-amyloid precursor protein. J. Biol. Chem. (1995) 270:6186–6192.